Clinically relevant dosing of miR-145 micelles curbs atherosclerosis in vivo
Authors:
- 4 June 2025
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 384, 113930
Abstract
No abstract availableKeywords
Funding Information
- Agilent Technologies
- University of Southern California
- American Heart Association (968730)
This publication has 68 references indexed in Scilit:
- Developing Therapeutically Enhanced Extracellular Vesicles for Atherosclerosis TherapyAdvanced Healthcare Materials, 2025
- Comparative pharmacokinetic evaluation of nanoparticle-based vs. conventional pharmaceuticals containing statins in attenuating dyslipidaemiaNaunyn-Schmiedeberg's Archives of Pharmacology, 2024
- Nanoparticle‐based therapeutic strategies for mitochondrial dysfunction in cardiovascular diseaseJournal of Biomedical Materials Research Part A, 2024
- Long-term, in vivo therapeutic effects of a single dose of miR-145 micelles for atherosclerosisBioactive Materials, 2023
- Correction to: Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults–an update for 2020Pediatric Nephrology, 2021
- Global Overview of the Epidemiology of Atherosclerotic Cardiovascular DiseaseArchives of Medical Research, 2015
- Mechanisms of LDL oxidationClinica Chimica Acta, 2010
- Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered ReleasePharmaceutical Research, 2010
- The Pathology of Atherosclerosis: Plaque Development and Plaque Responses to Medical TreatmentThe American Journal of Medicine, 2009
- The impact of medication regimen factors on adherence to chronic treatment: a review of literatureJournal of Behavioral Medicine, 2008